medorisper 1 mg
medochemie ltd., cyprus - risperidón - 68 - antipsychotica (neuroleptica)
medorisper 2 mg
medochemie ltd., cyprus - risperidón - 68 - antipsychotica (neuroleptica)
medorisper 3 mg
medochemie ltd., cyprus - risperidón - 68 - antipsychotica (neuroleptica)
amicor 10 mg
medochemie ltd., cyprus - atorvastatín - 31 - hypolipidaemica
amicor 20 mg
medochemie ltd., cyprus - atorvastatín - 31 - hypolipidaemica
amicor 40 mg
medochemie ltd., cyprus - atorvastatín - 31 - hypolipidaemica
forvel 0,4 mg/ml injekčný/infúzny roztok
medochemie ltd., cyprus - naloxón - 19 - antidota, detoxicantia
daltex 50 mg/1000 mg filmom obalené tablety
medochemie ltd., cyprus - metformín a vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
daltex 50 mg/850 mg filmom obalené tablety
medochemie ltd., cyprus - metformín a vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastické činidlá - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).